RAD-140 (Testolone) SARM: Effects, Dosing, Side Effects & PCT Guide

RAD-140, commonly known as Testolone, is one of the most potent selective androgen receptor modulators (SARMs) available. This comprehensive guide covers its mechanism of action, muscle-building potential, side effect profile, post-cycle therapy requirements, and critical considerations for safe and effective use.

What Is RAD-140 (Testolone)?

RAD-140 is a nonsteroidal selective androgen receptor modulator (SARM) developed by Radius Health in the early 2010s. Like all SARMs, RAD-140 is designed to activate androgen receptors (AR) in a tissue-selective manner, preferentially stimulating muscle and bone while theoretically minimizing effects on prostate, sebaceous glands, and other tissue types.

The appeal of RAD-140 compared to testosterone is the theoretical tissue selectivity. In theory, RAD-140 should produce muscle and bone gains with fewer androgenic side effects like prostate enlargement, hair loss, and acne. In practice, this selectivity is incomplete—RAD-140 does produce androgenic side effects, though the degree varies by individual and tissue type.

RAD-140 is a nonsteroidal compound, meaning it does not have the steroid ring structure of testosterone or anabolic steroids. This structural difference alters how it interacts with androgen receptors and other proteins. RAD-140 is oral (taken as a pill), making it more convenient than injectable testosterone but still requiring careful dosing and monitoring.

Mechanism of Action and Pharmacology

RAD-140 activates androgen receptors in muscle tissue, leading to increased protein synthesis and decreased protein breakdown. This anabolic effect translates to faster muscle growth and improved training recovery. Androgen receptor activation also enhances neuromotor coordination and potentially increases red blood cell production, supporting improved athletic performance.

The selective mechanism involves preferential activation in androgen-responsive tissues like muscle and bone while allegedly showing reduced activity in other tissues. However, research demonstrates that this selectivity is far from perfect—RAD-140 does activate androgen receptors in prostate and other tissues, potentially causing androgenic side effects despite the "selective" designation.

RAD-140 has a half-life of approximately 16-20 hours. This relatively short half-life means RAD-140 must be dosed daily, and steady-state levels are achieved after 3-4 days of consistent use. The short half-life also means that upon discontinuation, RAD-140 is largely cleared within 5-7 days, though its effects on androgen receptor signaling and natural testosterone suppression persist longer.

Like all androgens, RAD-140 suppresses natural testosterone production through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis. Even at moderate doses, RAD-140 typically causes near-complete suppression of endogenous testosterone. This suppression is one of RAD-140\'s most concerning aspects, requiring careful post-cycle management.

Muscle Building and Strength Gains

RAD-140 is one of the most potent SARMs for muscle building, often compared to moderate-dose testosterone therapy in terms of efficacy. Users typically report rapid muscle gain in the first 4 weeks as neuromuscular adaptation accelerates and androgen receptor signaling increases muscle protein synthesis. Initial gains of 1.5-2 pounds per week are common in the first 4 weeks.

By weeks 4-8, muscle gain rate typically slows to 0.75-1.5 pounds per week as rapid adaptation is exploited and the body approaches a new equilibrium. However, cumulative gains remain impressive—8-12 weeks of RAD-140 typically produces 10-18 pounds of muscle gain in trained individuals and 15-25 pounds in untrained individuals.

Strength gains are substantial and rapid. Users commonly report 10-20% improvements in lift performance within the first 4-6 weeks. A person benching 225 pounds for 5 reps might increase to 250 pounds for 5 reps, representing significant improvement. These strength gains contribute to continued training stimulus and muscle growth.

Vascularity and muscle fullness typically improve noticeably. Increased red blood cell production (erythropoiesis) from androgen action, combined with increased training volume and muscle growth, creates visual improvements in muscle definition and appearance. Veins become more prominent, and muscle hardness improves.

Recovery from training sessions accelerates dramatically. Soreness resolves faster, and ability to tolerate increased training volume improves significantly. A user might go from comfortable with 3 training days per week to tolerating 5-6 days per week without excessive fatigue. This improved recovery capacity is one of RAD-140\'s most valuable effects for training performance.

RAD-140 Dosing Protocols

Recommended RAD-140 dosing for muscle building ranges from 10-20mg daily. Most users start at 10mg daily and increase to 15-20mg if tolerated. Doses above 30mg daily are generally unnecessary as androgen receptor saturation occurs around 20mg—additional doses produce minimal additional benefit while increasing side effects.

The typical cycle length is 8-12 weeks. Cycles shorter than 8 weeks produce suboptimal results, as it takes 3-4 weeks to reach steady-state levels and another 4-8 weeks to realize significant muscle gains. Cycles longer than 12 weeks show diminishing returns and increase side effect risk without proportional benefit increase.

Most users employ a simple dosing protocol: one dose of 15-20mg daily, taken with food. Some split the dose (10mg twice daily) attempting to maintain more stable blood levels, though the short half-life usually makes single daily dosing adequate. Timing relative to training may matter slightly (dosing around training might be slightly advantageous), but consistency matters more than precise timing.

Female users should dose much lower than males, typically 5-10mg daily. Females have lower androgen receptor density and higher sensitivity to androgenic effects, making lower doses appropriate. Even at these modest doses, virilization risk exists and should be monitored carefully.

Some users employ cycling protocols (8-12 weeks on, 4-8 weeks off) for long-term use. Cycling may reduce adaptation and allow recovery of endogenous testosterone between cycles. However, best practices for long-term RAD-140 use are poorly defined due to limited human data.

Side Effects and Safety Concerns

Testosterone suppression is the most consistent and significant side effect of RAD-140. Even at 10-20mg daily, natural testosterone production is typically suppressed substantially, often to near-zero levels. This suppression begins within days of starting RAD-140 and persists throughout the cycle and into the post-cycle period. Without post-cycle therapy, testosterone may remain suppressed for weeks or months after discontinuation.

Liver stress (hepatotoxicity) is a concern with RAD-140. Elevated liver enzymes (ALT, AST) have been reported in some users, indicating hepatic inflammation or stress. The degree of liver stress varies substantially by individual. Pre-existing liver issues increase risk. Users should obtain baseline liver enzymes before starting RAD-140 and retest 4-6 weeks into use to monitor for concerning changes.

Hair loss in genetically predisposed individuals may occur due to RAD-140\'s androgenic properties. DHT-sensitive follicles may accelerate androgenic alopecia. Users with family histories of male pattern baldness face higher risk. This side effect is potentially permanent, so discontinuation at first signs of abnormal hair loss is prudent.

Acne and oily skin can develop or worsen due to increased sebum production from androgenic stimulation. This side effect is common and ranges from mild to severe depending on individual susceptibility. Aggressive skincare and dermatological intervention may be necessary for severe cases.

Mood and behavioral changes have been reported by some users. Increased aggression, irritability, or mood swings can occur. Some users report improved mood and confidence, while others report negative mood effects. Individual variation is substantial and unpredictable.

Gynecomastia (enlargement of breast tissue) risk exists despite RAD-140\'s supposedly selective androgen action. The mechanism is unclear but may involve partial agonist activity at estrogen receptors or indirect estrogenic effects. Some users employ aromatase inhibitors or selective estrogen receptor modulators (SERMs) as preventative measures, though this adds additional pharmacological burden.

Cardiovascular concerns include potential lipid profile changes and increased red blood cell count. Elevated hematocrit increases blood viscosity and potentially increases stroke risk. Regular cardiovascular monitoring and periodic blood donations may be necessary to manage elevated hematocrit.

Preclinical toxicology data on RAD-140 is concerning. Animal studies have shown potential carcinogenic activity in certain tissues. While human evidence is absent (RAD-140 was never approved for human use), the preclinical safety profile is inferior to some other compounds. This uncertainty is a legitimate concern that should factor into decision-making regarding RAD-140 use.

Post-Cycle Therapy (PCT) Requirements

Post-cycle therapy after RAD-140 is essential to restore natural testosterone production. Without PCT, testosterone suppression may persist for weeks or months, leaving users in a hypogonadal (low testosterone) state with attendant symptoms: fatigue, mood disturbance, reduced libido, and loss of previous gains.

Standard PCT protocols use selective estrogen receptor modulators (SERMs). Tamoxifen is commonly used at 20mg daily for 4-6 weeks. Clomiphene citrate (Clomid) is another option, typically dosed at 50mg daily for 4-6 weeks. Some users combine both in a "SERM stack" protocol, though this is more aggressive and carries higher side effect risk.

PCT timing should begin 1-2 days after the final RAD-140 dose, allowing RAD-140 to clear while immediately stimulating testosterone recovery. Delaying PCT risks prolonged hypogonadism. The typical PCT protocol runs 4-6 weeks, with effectiveness monitored through symptom improvement and, ideally, serum testosterone testing.

Some users add human chorionic gonadotropin (hCG) to PCT regimens, typically 500-1000 IU injected 3 times per week. hCG stimulates Leydig cell testosterone production in the testes, potentially accelerating recovery compared to SERMs alone. Combining hCG with SERMs may optimize recovery, though this adds complexity and cost.

Recovery of natural testosterone is variable. Some users recover to baseline within 4-8 weeks with appropriate PCT. Others take 8-12 weeks or longer. Baseline testosterone production capacity, age, and individual variation influence recovery rate. Post-PCT testosterone testing is valuable to confirm adequate recovery before discontinuing PCT.

RAD-140 vs. Other Compounds

Compared to testosterone, RAD-140 typically produces slightly less muscle gain but with allegedly fewer side effects (though evidence suggests side effects are substantial). RAD-140 is oral (convenient) versus testosterone requiring injections. Both suppress natural testosterone similarly and require PCT.

Compared to other SARMs like Ostarine (MK-2866) or Andarine (S-4), RAD-140 is more potent for muscle building. Ostarine produces more modest muscle gains (5-10 pounds) with less suppression. RAD-140 is appropriate for serious muscle-building goals, while Ostarine might be chosen for milder effects.

Compared to anabolic steroids, RAD-140 produces less muscle gain than higher-dose steroid cycles but is arguably more selective and carries less prostate enlargement risk. However, RAD-140 also has far less human safety data than anabolic steroids, which have been used for decades.

Legality and Availability

RAD-140 is not approved by the FDA for human use and is illegal to market for human consumption in most countries including the USA. It is sometimes sold as "research chemical" or "not for human consumption," but these labels are typically regulatory workarounds rather than legitimate product designations.

Purchasing RAD-140 operates in legal gray areas. While possession for personal use may not be explicitly illegal, selling it for human consumption typically violates regulations. The legal status varies by jurisdiction and may change. Users should be aware of legal risks in their specific location.

Blood Work and Monitoring

Baseline blood work before starting RAD-140 should include total testosterone, free testosterone, liver enzymes (ALT, AST, ALP), lipid panel, complete blood count (CBC), and PSA. These establish individual baseline before hormonal and biochemical changes occur.

Mid-cycle monitoring (4-6 weeks into the cycle) should include liver enzymes to detect concerning hepatotoxicity. If ALT/AST are more than 2-3x upper normal limit, discontinuation should be considered. Continuing RAD-140 with significantly elevated liver enzymes risks serious hepatic damage.

Post-cycle testosterone testing should be performed 4-6 weeks after completing PCT to confirm adequate recovery. If testosterone remains suppressed below 300 ng/dL, additional PCT or medical intervention may be necessary.

Learn more about SARMs versus peptides, MK-677 alternative, and peptides vs steroids comparison for related information.